IGEA Pharma NV
SIX:IGPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
IGEA Pharma NV
Total Current Liabilities
IGEA Pharma NV
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
IGEA Pharma NV
SIX:IGPH
|
Total Current Liabilities
€1.2m
|
CAGR 3-Years
34%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
O
|
ONWARD Medical NV
XBRU:ONWD
|
Total Current Liabilities
€11.1m
|
CAGR 3-Years
11%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
IGEA Pharma NV
Glance View
IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.
See Also
What is IGEA Pharma NV's Total Current Liabilities?
Total Current Liabilities
1.2m
EUR
Based on the financial report for Dec 31, 2022, IGEA Pharma NV's Total Current Liabilities amounts to 1.2m EUR.
What is IGEA Pharma NV's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
43%
Over the last year, the Total Current Liabilities growth was -23%. The average annual Total Current Liabilities growth rates for IGEA Pharma NV have been 34% over the past three years , 43% over the past five years .
